During the past 25 years, the Joslin Diabetes Center Diabetes Research Center (DRC) has stimulated and nurtured diabetes research at the Joslin and in the surrounding Harvard Medical School community. The DRC, with its Core Laboratories, Enrichment Program, and support for Pilot and Feasibility (P&F) studies, has provided critical infrastructure for basic, translational, and clinical research, and provided an outstanding intellectual enrichment base for diabetes researchers at Joslin and across the Harvard/Longwood medical area. Having a robust and adaptable DRC administrafive structure is critical for maintaining and coordinating the quality, effectiveness, and efficiency of the DRC core services, and for providing the vision that allows the DRC to adapt to changing needs and discoveries in the field of diabetes research especially now to implement the planned expansion of research efforts at Joslin. The purpose of the Joslin Diabetes Center DRC Administrafive Component is to: 1) Manage the DRC in a manner that ensures: a) strength in its leadership, b) quality, efficiency, and oversight in its Cores, and c) promotion of a stimulating, interactive, and collaborative scientific environment that advances diabetes research in the nearby Harvard community and greater Boston area. 2) Adapt to progress in scientific and informafion technology so that: a) the DRC Cores maintain cutting edge relevance with respect to the services they offer and b) information and computing technologies are leveraged to provide maximal efficiency and quality for DRC operations.

Public Health Relevance

The Administrative Component ofthe Joslin Diabetes Center DRC is essenfial to manage the Core Laboratories, Pilot and Feasibility Program and Enrichment Program that facilitate research directed to prevention, better treatments, and a cure for diabetes.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-S)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Joslin Diabetes Center
United States
Zip Code
Karatepe, Kutay; Zhu, Haiyan; Zhang, Xiaoyu et al. (2018) Proteinase 3 Limits the Number of Hematopoietic Stem and Progenitor Cells in Murine Bone Marrow. Stem Cell Reports 11:1092-1105
Sustarsic, Elahu G; Ma, Tao; Lynes, Matthew D et al. (2018) Cardiolipin Synthesis in Brown and Beige Fat Mitochondria Is Essential for Systemic Energy Homeostasis. Cell Metab 28:159-174.e11
Lessard, Sarah J; MacDonald, Tara L; Pathak, Prerana et al. (2018) JNK regulates muscle remodeling via myostatin/SMAD inhibition. Nat Commun 9:3030
Cardamone, Maria Dafne; Tanasa, Bogdan; Cederquist, Carly T et al. (2018) Mitochondrial Retrograde Signaling in Mammals Is Mediated by the Transcriptional Cofactor GPS2 via Direct Mitochondria-to-Nucleus Translocation. Mol Cell 69:757-772.e7
Solheim, Marie H; Winnay, Jonathon N; Batista, Thiago M et al. (2018) Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes. Diabetes 67:1297-1309
Stanford, Kristin I; Lynes, Matthew D; Takahashi, Hirokazu et al. (2018) 12,13-diHOME: An Exercise-Induced Lipokine that Increases Skeletal Muscle Fatty Acid Uptake. Cell Metab 27:1111-1120.e3
McGill, Dayna E; Volkening, Lisa K; Butler, Deborah A et al. (2018) Baseline Psychosocial Characteristics Predict Frequency of Continuous Glucose Monitoring in Youth with Type 1 Diabetes. Diabetes Technol Ther 20:434-439
Weir, Gordon C; Ehlers, Mario R; Harris, Kristina M et al. (2018) Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics. Pediatr Diabetes 19:945-954
Qi, Weier; Li, Qian; Gordin, Daniel et al. (2018) Preservation of renal function in chronic diabetes by enhancing glomerular glucose metabolism. J Mol Med (Berl) 96:373-381
Adachi, Yusuke; De Sousa-Coelho, Ana Luisa; Harata, Ikue et al. (2018) l-Alanine activates hepatic AMP-activated protein kinase and modulates systemic glucose metabolism. Mol Metab 17:61-70

Showing the most recent 10 out of 1120 publications